IL17A and psoriasis vulgaris: In combination with the results of other trials exploring antibodies directed against IL-17A 5 or the IL-17 receptor A chain 7, these studies document the potential of IL-17 blockade as a new therapeutic approach in moderate-to-severe plaque psoriasis.